If you’ve been following the “legal tea” lately, things are getting spicy in the world of GLP-1 medications. Novo Nordisk (the makers of Ozempic and Wegovy) has officially filed a lawsuit against telehealth giant Hims & Hers over their compounded versions of semaglutide.
As someone who has lost 113 pounds on this journey, I know how life-changing these medications are. I also know how terrifying it is to think your access to them might be cut off. Whether you are on name-brand Zepbound or a compounded tirzepatide, this lawsuit could change the landscape for all of us.
Sign up for my Weight Loss Encouragement Emails!
📊 What Our Community Says: The Compounding Split
I recently polled our Encouragement Group to see how everyone is currently accessing their medication. The results show just how much we rely on these options:
- 71% are taking Brand Name (Wegovy, Ozempic, Zepbound, Mounjaro) from a standard pharmacy.
- 29% are taking Compounded (Semaglutide or Tirzepatide) via telehealth or compounding pharmacies.
While the majority are on brand names, nearly 1 in 3 members of our community rely on compounded versions. For many, compounding isn’t just a choice—it’s the only way to afford the medication or bypass the “out of stock” signs at the local pharmacy.
⏳ The “Evergreening” Game: Why March 2026 Matters
You might be wondering: Why is Novo Nordisk fighting so hard right now? It all comes down to patents. In my previous article on When GLP-1 Generics Will Hit Our Shopping Lists, I explained a strategy pharmaceutical companies use called “evergreening”.
Technically, the 20-year patent award for the semaglutide compound should expire in March 2026 😲. If that were the case, affordable generic versions would be right around the corner! However, through evergreening—filing for new secondary patents on minor modifications like delivery methods or dosages—Novo Nordisk has successfully extended their protection into the 2030s.
This lawsuit against Hims & Hers is another way to protect that extended monopoly by shutting down the “compounded” bridge that many people use to find affordability while waiting for true generics.
🌎 What a World Without Compounds Might Look Like
If the courts side with Big Pharma and the FDA officially restricts compounding, the choice won’t be between a high-priced brand name and a less expensive compound. Instead, it becomes a more complex landscape of supply and brand-loyalty programs.
- The Cash-Pay Competition: In early 2026, we’ve seen a massive shift in pricing. Novo Nordisk now offers Wegovy introductory pricing as low as $199/month for beginner doses, scaling up to $349/month for higher strengths. Meanwhile, Eli Lilly’s Zepbound vials now range from $299 to $449/month. Without compounded options, every patient is funneled directly into these manufacturer-controlled programs, leaving no room for outside competition.
- Supply Chain “Hunger Games”: Even when the FDA declares shortages “resolved,” many of us know the struggle of finding stock. Without compounded options as a safety valve, more users will be competing for the same limited brand-name inventory.
- Loss of Customization: Telehealth platforms often provide custom formulations, like those with added B12, to help manage side effects. Without these, users lose the ability to find “not a copy” versions that might work better for their bodies.
🚀 The Future: Hope for More Competition
The best way to lower prices is competition. While the current lawsuit feels discouraging, there is hope on the horizon as other pharmaceutical giants enter the race. We likely won’t see significant pricing competition from these new entrants until 2027 or 2028, but they are coming:
- Retatrutide (Eli Lilly): This “triple agonist” is expected to wrap up Phase 3 trials in early 2026, with potential FDA approval in late 2026 but likely in 2027.
- CagriSema (Novo Nordisk): A combination shot that may be even more effective than Wegovy, with an FDA decision expected sometime in late 2026.
- AstraZeneca: Their oral GLP-1 (elecoglipron) is moving into Phase 3 trials in 2026 after positive mid-stage results.
- Pfizer: After some setbacks, Pfizer is pushing a new injectable candidate into Phase 3 in 2026, targeting a potential approval in 2028.
🤝 Let’s Talk About It
Are you part of the 29% on compounded meds? How would your journey change if compounds were no longer an option? Let’s discuss this in our [Encouragement Community]—we are in this together!
Disclaimers: Friends, I am not a medical professional, nor do I pretend to be one on the internet. This information is for educational purposes only, gathered from trusted sources and my personal experiences. Always consult with your healthcare provider before making any changes to your medication or lifestyle. This post has links included that are affiliate links. Countess of Shopping & her furbabies will be compensated when you make a purchase by clicking through the links at no cost to you.
